Journal Article

Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial

Johnson, Mark D, Lane, Bethany F, Janis, L Scott, Cloft, Harry J, Chiu, David, Alexandrov, Andrei V, Zaidat, Osama O, Nizam, Azhar, Waters, Michael F, Fiorella, David, Turan, Tanya N, McDougall, Cameron G, Rumboldt, Zoran, Lutsep, Helmi L, Levy, Elad I, Montgomery, Jean, Klucznik, Richard P, Barnwell, Stanley L, Pride, G Lee, Chimowitz, Marc I, Hoh, Brian L, Hourihane, J Maurice, Derdeyn, Colin P, Lynch, John R, Clark, Joni M, Harrigan, Mark R, Lynn, Michael J

2014

Overview

Early results of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis trial showed that, by 30 days, 33 (14·7%) of 224 patients in the stenting group and 13 (5·8%) of 227 patients in the medical group had died or had a stroke (percentages are product limit estimates), but provided insufficient data to establish whether stenting offered any longer-term benefit. Here we report the long-term outcome of patients in this trial. We randomly assigned (1:1, stratified by centre with randomly permuted block sizes) 451 patients with recent transient ischaemic attack or stroke related to 70–99% stenosis of a major intracranial artery to aggressive medical management (antiplatelet therapy, intensive management of vascular risk factors, and a lifestyle-modification programme) or aggressive medical management plus stenting with the Wingspan stent. The primary endpoint was any of the following: stroke or death within 30 days after enrolment, ischaemic stroke in the territory of the qualifying artery beyond 30 days of enrolment, or stroke or death within 30 days after a revascularisation procedure of the qualifying lesion during follow-up. Primary endpoint analysis of between-group differences with log-rank test was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT 00576693. During a median follow-up of 32·4 months, 34 (15%) of 227 patients in the medical group and 52 (23%) of 224 patients in the stenting group had a primary endpoint event. The cumulative probability of the primary endpoints was smaller in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0·0252). Beyond 30 days, 21 (10%) of 210 patients in the medical group and 19 (10%) of 191 patients in the stenting group had a primary endpoint. The absolute differences in the primary endpoint rates between the two groups were 7·1% at year 1 (95% CI 0·2 to 13·8%; p=0·0428), 6·5% at year 2 (–0·5 to 13·5%; p=0·07) and 9·0% at year 3 (1·5 to 16·5%; p=0·0193). The occurrence of the following adverse events was higher in the PTAS group than in the medical group: any stroke (59 [26%] of 224 patients vs 42 [19%] of 227 patients; p=0·0468) and major haemorrhage (29 [13%]of 224 patients vs 10 [4%] of 227 patients; p=0·0009). The early benefit of aggressive medical management over stenting with the Wingspan stent for high-risk patients with intracranial stenosis persists over extended follow-up. Our findings lend support to the use of aggressive medical management rather than PTAS with the Wingspan system in high-risk patients with atherosclerotic intracranial arterial stenosis. National Institute of Neurological Disorders and Stroke (NINDS) and others.

• Publisher: Elsevier Ltd,Elsevier,Elsevier Limited
• Subject: Adult / Aged / Aged, 80 and over / Angioplasty - adverse effects / Angioplasty - methods / Aspirin - therapeutic use / Biological and medical sciences / Blood pressure / Carotid Stenosis - complications / Carotid Stenosis - therapy / Cholesterol / Clopidogrel / Drug therapy / Female / Follow-Up Studies / General aspects / Humans / Internal Medicine / Intracranial Arteriosclerosis - complications / Intracranial Arteriosclerosis - therapy / Ischemic Attack, Transient - etiology / Ischemic Attack, Transient - prevention & control / Male / Medical sciences / Medical treatment / Middle Aged / Platelet Aggregation Inhibitors - adverse effects / Platelet Aggregation Inhibitors - therapeutic use / Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) / Risk factors / Secondary Prevention / Single-Blind Method / Stents / Stroke - etiology / Stroke - prevention & control / Ticlopidine - analogs & derivatives / Ticlopidine - therapeutic use / Treatment Outcome / Veins & arteries